These deficiencies in antigen presentation may reduce tumour immunogenicity and limit the efficacy of T cell‐based therapies, underscoring the need to develop immunotherapeutic strategies that restore or bypass impaired MHC function in paediatric oncology. Here, HLA-C is linked to neoplasm.